ライフサイエンスコーパス: sodium-iodide symporter

1 sed expression of thyroglobulin (Tg) and the sodium/iodide symporter).

2 virus type I thymidine kinase and the human sodium-iodide symporter.

3 yroid-stimulating hormone in stimulating the sodium-iodide symporter.

4 as attributed to decreased expression of the sodium-iodide symporter.

5 egulated expression of thyroglobulin and the sodium/iodide symporter.

6 receptor expressing cells also expressed the sodium iodide symporter and thyroglobulin genes.

7 y antagonists increase the expression of the sodium-iodide symporter and uptake of iodine.

8 A levels for thyroglobulin, thyroperoxidase, sodium iodide symporter, and deiodinase type 2, and deio

9 2, sodium hydrogen exchanger 3, aquaporin 7, sodium iodide symporter, and hydrogen potassium adenosin

10 HR expression was required for expression of sodium-iodide symporter but was not required for thyrogl

11 Sodium iodide symporter expression in patient tumors aft

12 this observation was the lack of detectable sodium-iodide symporter expression in TSHR-KO thyroid gl

13 MV engineered to express the sodium iodide symporter gene (MV-NIS) facilitates locali

14 profound inhibition of the expression of the sodium iodide symporter gene.

15 The rat sodium/iodide symporter gene (rNIS) was cloned into a re

16 ted with a vaccinia virus carrying the human sodium iodide symporter GLV-1h153.

17 We incorporated the human sodium iodide symporter (hNIS) and the human somatostati

18 differentiation, including the loss of human sodium iodide symporter (hNIS) expression, radioactive i

19 carcinoembryonic antigen (CEA) or the human sodium iodide symporter (hNIS) for oncolytic potential i

20 ionuclide accumulation mediated by the human sodium iodide symporter (hNIS) gene in conjunction with

21 ntification of cardiac gene expression after sodium iodide symporter (hNIS) gene transfer in cardiac

22 ic vaccinia virus, GLV-1h153, carrying human sodium iodide symporter (hNIS), in combination with radi

23 Anion transport by the human sodium-iodide symporter (hNIS) is an established target

24 man norepinephrine transporter (hNET), human sodium-iodide symporter (hNIS), a human deoxycytidine ki

25 novel PET radioligand for imaging the human sodium/iodide symporter (hNIS).

26 BLI and sodium-iodide symporter imaging may be useful for in viv

27 Here we show that a specialized form of the sodium/iodide symporter in the mammary gland mediates ac

28 nal obtained by firefly luciferase and human sodium-iodide symporter labeling of cardiosphere-derived

29 hese results indicate that the mammary gland sodium/iodide symporter may be an essential breast cance

30 The sodium/iodide symporter mediates active iodide transport

31 virus (VSV)-murine interferon beta (IFNbeta)-sodium iodide symporter (NIS) (VSV-mIFNbeta-NIS) oncolyt

32 second strategy involves transduction of the sodium iodide symporter (NIS) and free radionuclide ther

33 cells with retroviral vectors containing the sodium iodide symporter (NIS) and thyroperoxidase (TPO)

34 aft breast cancer model expressing the human sodium iodide symporter (NIS) as a reporter.

35 The application of sodium iodide symporter (NIS) as a theranostic gene allo

36 In the current study, we used the sodium iodide symporter (NIS) as a theranostic gene to i

37 cancer cells to express functionally active sodium iodide symporter (NIS) by targeted NIS gene trans

38 ast cancer cells stably expressing the human sodium iodide symporter (NIS) fused to a red fluorescent

39 n the matrix protein and expresses the human sodium iodide symporter (NIS) gene.

40 its binding factor PBF repress expression of sodium iodide symporter (NIS) messenger RNA (mRNA), and

41 In this study, sodium iodide symporter (NIS) transgene imaging was eval

42 cancer cells to express functionally active sodium iodide symporter (NIS) would enable those cells t

43 din-Darby canine kidney cells expressing the sodium iodide symporter (NIS), pendrin, or NIS and pendr

44 ne levels by up-regulating expression of the sodium iodide symporter (NIS), thyroid peroxidase (TPO),

45 is one of the most promising candidates for sodium iodide symporter (NIS)-mediated gene therapy.

46 We examined the sodium-iodide symporter (NIS), which promotes in vivo ce

47 h uptake into thyroid tissue mediated by the sodium-iodide symporter (NIS).

48 t tissue and some breast cancers express the sodium/iodide symporter (NIS) and concentrate iodide.

49 The sodium/iodide symporter (NIS) concentrates iodide in the

50 The sodium/iodide symporter (NIS) has been identified as an

51 Perchlorate, thiocyanate, and nitrate are sodium/iodide symporter (NIS) inhibitors that block iodi

52 The sodium/iodide symporter (NIS) is under investigation as

53 The sodium/iodide symporter (NIS) mediates active I(-) trans

54 The sodium/iodide symporter (NIS) mediates active iodide (I(

55 The sodium/iodide symporter (NIS) stimulates iodide uptake i

56 ds to the 3'-untranslated region of PAX8 and sodium/iodide symporter (NIS), leading to impaired prote

57 wn that RET/PTC1 decreases expression of the sodium/iodide symporter (NIS), the molecule that mediate

58 in the thyroid and breast is mediated by the sodium/iodide symporter (NIS).

59 functional role in tumor progression of the sodium/iodide symporter (NIS; aka SLC5A5), which is upre

60 isease, based on decreased expression of the sodium iodide symporter SLC5A5 (NIS), diminished membran

61 Pax-8, thereby suppressing expression of the sodium iodide symporter, thyroid peroxidase, TG, and thy

62 thyroid-specific target genes thyroglobulin, sodium iodide symporter, thyroperoxidase, and thyroid-st

63 the hormonal regulation of the mammary gland sodium/iodide symporter, we demonstrate by scintigraphy